Brain health pharma company appoints new CEO
Sergio Marullo di Condojanni has been appointed Chief Executive Officer of Italian pharma company Angelini Pharma.
Di Condojanni has served as CEO of Angelini Industries since 2020 and will maintain that role while assuming leadership of the pharmaceutical division to drive the company’s strategy implementation, leveraging extensive executive, governance, and financial expertise.
Angelini Pharma, which specialises in brain health, hopes it can further solidify pharmaceutical healthcare as a core pillar of its long-term growth strategy alongside industrial technology.
“I am excited and deeply honoured to take on this important role at the helm of Angelini Pharma during a pivotal moment of transformation,” di Condojanni said.
“Our strategic priorities are clear: strengthen long-term competitiveness and seize transformative M&A opportunities that will enable us to scale globally.
“At the same time, our focus will be on driving our ambitious strategy to achieve market leadership and deliver breakthrough solutions in brain health for patients worldwide.”
Bruno Quinney, Content Team, DDW
